ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Stands Firm On Assist “Downscaling” Despite 150 Letters From States, Volunteers

January 15, 1993

Guest Opinion: Long Island Study’s Value Now Rests In Its Repository

November 2, 2002

DCT Board Says RDOG Concept Too Expensive; Discusses Grant Funding

July 24, 1992

Simons Named CEO of Prostate Cancer Foundation.

November 17, 2006

NCI’s Drug Screen Tests 400 Agents A Week; Recompetition Of Contracts Approved

February 26, 1993

In Brief: MSK Opens Campaign On Colorectal Cancer Early Detection NIH Symposium Dedicates Cyclotron

August 28, 1987